Related Experiment Video
Updated: May 21, 2025

Testing of Nanoparticle Release from a Composite Containing Nanomaterial Using a Chamber System
Published on: November 22, 2016
Regulatory pathways and guidelines for nanotechnology-enabled health products: a comparative review of EU and US
Francisco D Rodríguez-Gómez1,2, Dominique Monferrer1,3, Oriol Penon1
1Asphalion SL, Barcelona, Spain.
Abstract:
The integration of nanotechnology into healthcare has introduced Nanotechnology-Enabled Health Products (NHPs), promising revolutionary advancements in medical treatments and diagnostics. Despite their potential, the regulatory navigation for these products remains complex and often lagging, creating barriers to their clinical application. This review article focuses on dissecting the regulatory landscape for NHPs, particularly in the European Union and the United States, to identify applicable requirements and the main regulatory guidelines currently available for meeting regulatory expectations.
More Related Videos
07:47Experimental Protocol to Investigate Particle Aerosolization of a Product Under Abrasion and Under Environmental Weathering
Published on: September 16, 2016
08:47Experimental Quantification of Interactions Between Drug Delivery Systems and Cells In Vitro: A Guide for Preclinical Nanomedicine Evaluation
Published on: September 28, 2022
Related Concept Videos
Drug Regulation
Drug Control Governance: Regulatory Bodies and Their Impact
Preclinical Development: Overview
Standards of Care II
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview